ScienceAlert7h
FDA-Approved Nasal Spray For Depression Is First Of Its Kind
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.
FDA approves Spravato, nasal spray derived from Ketamine
The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
IFLScience16h
FDA Approves First-Ever Standalone Therapy For Treatment-Resistant Depression
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
Pregnancy raises risks to mental health in MS patients, study says
Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.
Seniors who are children of divorce face greater stroke risk, study finds
Seniors have a 61% higher risk of stroke if their parents divorced when they were children or teenagers, researchers reported in a study published Wednesday in the journal PLOS One.
Johnson & Johnson's Spravato nasal spray okayed as stand-alone treatment for depression
Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...